Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in BioCryst Pharmaceuticals, Inc. or Zymeworks Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how BioCryst Pharmaceuticals, Inc. and Zymeworks Inc. compare based on key financial metrics to determine which better meets your investment needs.

About BioCryst Pharmaceuticals, Inc. and Zymeworks Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Latest Biotechnology and BioCryst Pharmaceuticals, Inc., Zymeworks Inc. Stock News

As of April 30, 2026, BioCryst Pharmaceuticals, Inc. had a $2.3 billion market capitalization, compared to the Biotechnology median of $276.3 million. BioCryst Pharmaceuticals, Inc.’s stock is up 17.9% in 2026, up 2.9% in the previous five trading days and up 8.53% in the past year.

Currently, BioCryst Pharmaceuticals, Inc.’s price-earnings ratio is 7.6. BioCryst Pharmaceuticals, Inc.’s trailing 12-month revenue is $874.8 million with a 30.2% net profit margin. Year-over-year quarterly sales growth most recently was 209.2%. Analysts expect adjusted earnings to reach $0.474 per share for the current fiscal year. BioCryst Pharmaceuticals, Inc. does not currently pay a dividend.

As of April 30, 2026, Zymeworks Inc. had a $2.0 billion market cap, putting it in the 55th percentile of all stocks. Zymeworks Inc.’s stock is up 3.4% in 2026, down 3.1% in the previous five trading days and up 117.02% in the past year.

Currently, Zymeworks Inc. does not have a price-earnings ratio. Zymeworks Inc.’s trailing 12-month revenue is $106.0 million with a -76.6% net profit margin. Year-over-year quarterly sales growth most recently was -91.9%. Analysts expect adjusted earnings to reach $1.226 per share for the current fiscal year. Zymeworks Inc. does not currently pay a dividend.

How We Compare BioCryst Pharmaceuticals, Inc. and Zymeworks Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at BioCryst Pharmaceuticals, Inc. and Zymeworks Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

BioCryst Pharmaceuticals, Inc. and Zymeworks Inc. Growth Grades

Company	Ticker	Growth
BioCryst Pharmaceuticals, Inc.	BCRX	D
Zymeworks Inc.	ZYME	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

BioCryst Pharmaceuticals, Inc. has a Growth Score of 31, which is Weak. Zymeworks Inc. has a Growth Score of 13, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither BioCryst Pharmaceuticals, Inc. or Zymeworks Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if BioCryst Pharmaceuticals, Inc. or Zymeworks Inc. is the better investment when it comes to sustainable growth.

BioCryst Pharmaceuticals, Inc. and Zymeworks Inc.’s Momentum Grades

Company	Ticker	Momentum
BioCryst Pharmaceuticals, Inc.	BCRX	B
Zymeworks Inc.	ZYME	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

BioCryst Pharmaceuticals, Inc. has a Momentum Score of 69, which is Strong. Zymeworks Inc. has a Momentum Score of 86, which is Very Strong.

The Momentum Grade Winner: Zymeworks Inc.

As you can clearly see from the Momentum Grade breakdown above, Zymeworks Inc. is considered to have stronger momentum compared to BioCryst Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Zymeworks Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

BioCryst Pharmaceuticals, Inc. and Zymeworks Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
BioCryst Pharmaceuticals, Inc.	BCRX	B
Zymeworks Inc.	ZYME	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

BioCryst Pharmaceuticals, Inc. has a Earnings Estimate Score of 63, which is Positive. Zymeworks Inc. has a Earnings Estimate Score of 47, which is Neutral.

The Earnings Estimate Revisions Grade Winner: BioCryst Pharmaceuticals, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, BioCryst Pharmaceuticals, Inc. has a better Earnings Estimate Revisions Grade than Zymeworks Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, BioCryst Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other BioCryst Pharmaceuticals, Inc. and Zymeworks Inc. Grades

In addition to Momentum, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether BioCryst Pharmaceuticals, Inc. and Zymeworks Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, BioCryst Pharmaceuticals, Inc. or Zymeworks Inc. Stock?

Overall, BioCryst Pharmaceuticals, Inc. stock has a Growth Score of 31, Momentum Score of 69 and Estimate Revisions Score of 63.

Zymeworks Inc. stock has a Growth Score of 13, Momentum Score of 86 and Estimate Revisions Score of 47.

Comparing BioCryst Pharmaceuticals, Inc. and Zymeworks Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.